Skip to main content
Unichem Laboratories Ltd. logo

Unichem Laboratories Ltd. — Investor Relations & Filings

Ticker · UNICHEMLAB ISIN · INE351A01035 LEI · 3358008AHXLO9H4C2Q20 BSE.NS Manufacturing
Open in API
Filings indexed 1,119 across all filing types
Latest filing 2022-03-09 Regulatory Filings
Country IN India
Listing BSE.NS UNICHEMLAB

About Unichem Laboratories Ltd.

https://www.unichemlabs.com/

Unichem Laboratories Ltd. focuses on the research, development, manufacturing, and marketing of pharmaceutical formulations and Active Pharmaceutical Ingredients (APIs). The company provides solutions across various therapeutic areas, including cardiology, gastroenterology, anti-infectives, diabetology, orthopedics, and neurology. It maintains a significant international footprint, exporting products to regulated markets such as the United States and Europe. The manufacturing infrastructure is built to comply with global standards, featuring approvals from international regulatory agencies. Through its dedicated research and development initiatives, the organization develops a robust pipeline of generic products and complex formulations aimed at improving patient outcomes globally.

Recent filings

Filing Released Lang Actions
Communication to shareholders as per Reg 30
Regulatory Filings Classification · 95% confidence The document is a detailed notice and form communication from a company to its shareholders regarding the updation of KYC (Know Your Customer) details, PAN, nomination, and bank details as per SEBI circular requirements. It includes instructions, forms (ISR-1, SH-13, SH-14, ISR-3), and procedural details for shareholders holding shares in physical form. The document is not a financial report, earnings release, or management discussion. It is a regulatory compliance communication related to shareholder information updates mandated by SEBI. It does not contain financial statements or audit information, nor is it a meeting notice or voting result. It is a regulatory filing informing shareholders about KYC updation requirements and providing forms for compliance. Therefore, the most appropriate classification is Regulatory Filings (RNS).
2022-03-09 English
Confirmation of Notice to shareholders of the Company holding shares in physical form for updating of details like PAN, KYC and Nomination etc.
Regulatory Filings Classification · 95% confidence The document is a detailed notice and form communication to shareholders regarding the updation of KYC (Know Your Customer) details, PAN, nomination, and bank account information as per SEBI circular dated November 3, 2021. It includes instructions, forms (ISR-1, SH-13, SH-14, ISR-3), and procedural details for shareholders holding shares in physical form. The content is regulatory compliance related to shareholder information updating and does not contain financial statements, earnings data, management discussion, or any report of financial performance. It is not an announcement of a report publication but a regulatory compliance communication to shareholders. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements and compliance documents that do not fit other specific categories.
2022-03-09 English
Press Release
Capital/Financing Update Classification · 95% confidence The document is a press release announcing the receipt of ANDA approval from the USFDA for a pharmaceutical product. It is addressed to stock exchanges under SEBI regulations, indicating it is an official disclosure. The content focuses on a regulatory approval event and product commercialization plans, not on financial results, management changes, or detailed financial data. The document length is 3540 characters, which is relatively short and typical for a press release or regulatory announcement. There is no indication of financial statements, earnings data, or detailed report content. Therefore, this document fits best under the category of Capital/Financing Update (CAP) as it relates to a significant regulatory approval impacting the company's product portfolio and potential market expansion, which is a material event for investors and capital markets.
2022-02-28 English
Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith the press release pertaining to receipt of ANDA approval ....
Regulatory Filings Classification · 95% confidence The document is a press release dated February 28, 2022, announcing that Unichem Laboratories Limited has received ANDA approval from the USFDA for a generic drug product. It is addressed to stock exchanges under SEBI regulations, indicating it is an official disclosure. The content focuses on the approval and commercialization plans, with no financial statements or detailed financial analysis included. The document length is 3540 characters, which is relatively short and typical for a press release or regulatory announcement rather than a full financial report. There is no indication that this is an earnings release, annual or interim report, or any other detailed financial filing. It is an update on a regulatory approval event relevant to the company’s operations and market disclosures. Therefore, the most appropriate classification is Regulatory Filings (RNS), as it is a general regulatory announcement that does not fit into more specific categories like earnings release or capital update.
2022-02-28 English
Loss of share certificate
Regulatory Filings Classification · 95% confidence The document is a formal letter addressed to stock exchanges regarding compliance with Regulation 39(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. It informs about the loss/misplacement of share certificates and the issuance of duplicate certificates. The content is regulatory in nature, related to share certificate management, and does not contain financial data, earnings, management discussion, or report publication. It is not a report itself but a regulatory compliance notification. Therefore, it fits best under Regulatory Filings (RNS). The document length is short (1766 characters), and it is not an announcement of a report publication but a compliance notification.
2022-02-24 English
Pursuant to Regulation 39(3) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we furnish herewith the intimation about ....
Regulatory Filings Classification · 95% confidence The document is a formal communication addressed to stock exchanges regarding compliance with Regulation 39(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. It specifically informs about the loss/misplacement of share certificates and the process for issuing duplicate certificates. There is no financial data, no report attached or referenced, and the document is a regulatory compliance notification related to share certificates. This fits best under Regulatory Filings (RNS) as it is a general regulatory announcement that does not fit other specific categories.
2022-02-24 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.